期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 16, 期 8, 页码 2437-2444出版社
WILEY-BLACKWELL
DOI: 10.1111/ajt.13757
关键词
translational research; science; clinical research; practice; liver transplantation; hepatology; histocompatibility; immunobiology; liver transplantation: living donor; liver allograft function; dysfunction; rejection; antibody biology; alloantibody
资金
- National Institute of Diabetes & Digestive & Kidney Diseases [U01-DK62444, U01-DK62467, U01-DK62483, U01-DK62484, U01-DK62494, U01-DK62496, U01-DK62498, U01-DK62505, U01-DK62531, U01-DK62536]
- Health Resources and Services Administration (HRSA)
- American Society of Transplant Surgeons (ASTS)
- One Lambda (A Thermo Fisher Scientific Brand, Canoga Park, CA)
- Paul I. Terasaki Foundation Laboratory, Los Angeles, CA
With less ischemia, improved donor selection and controlled procedures, living donor liver transplantation (LDLT) might lead to less HLA donor-specific antibody (DSA) formation or fewer adverse outcomes than deceased donor liver transplantation (DDLT). Using the multicenter A2ALL (Adult-to-Adult Living Donor Liver Transplantation Cohort Study) biorepository, we compared the incidence and outcomes of preformed and de novo DSAs between LDLT and DDLT. In total, 129 LDLT and 66 DDLT recipients were identified as having serial samples. The prevalence of preformed and de novo DSAs was not different between DDLT and LDLT recipients (p = 0.93). There was no association between patient survival and the timing (preformed vs. de novo), class (I vs. II) and relative levels of DSA between the groups; however, preformed DSA was associated with higher graft failure only in DDLT recipients (p = 0.01). De novo DSA was associated with graft failure regardless of liver transplant type (p = 0.005) but with rejection only in DDLT (p = 0.0001). On multivariate analysis, DSA was an independent risk factor for graft failure regardless of liver transplant type (p = 0.017, preformed; p = 0.002, de novo). In conclusion, although similar in prevalence, DSA may have more impact in DDLT than LDLT recipients. Although our findings need further validation, future research should more robustly test the effect of donor type and strategies to mitigate the impact of DSA. This analysis of serum samples from the Adult to Adult Living Donor Liver Transplantation Cohort Study finds donor-specific antibodies are an overall independent risk factor for graft failure and preliminarily appear more detrimental in deceased donor liver recipients compared to living donor liver recipients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据